Moderna (MRNA) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Moderna (MRNA) do?
Moderna Inc (MRNA) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Produces mRNA-based vaccines targeting viral diseases, including respiratory syncytial virus and COVID-19. Operates a messenger RNA platform that quickly programs biological cells to produce specific therapeutic proteins. It is worth $80.65B on the market and sold $2.53B over the last year.
- Market cap
- $80.65B
- P/E ratio
- None (reported a loss)
- Annual sales
- $2.53B
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 18, 2026
Brands and businesses behind MRNA
- Spikevax: Sells an mRNA vaccine protecting against COVID-19 to governments and commercial pharmacies globally.
- mRESVIA: Provides an mRNA vaccine protecting older adults against respiratory syncytial virus through healthcare provider distribution.
MRNA’s flags, in plain English
Each flag is a number from Moderna’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Stupid Cash
Can pay this year's bills 3.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Still Climbing
Sales up 19.3% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Insiders Hold
Insiders own 8.5% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Burning Cash
Losing money, profit margin of -110.5%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
1 more risk note open with the free trial. Try it free for 7 days.
Questions about MRNA
How big is Moderna?
Moderna’s market cap is $80.65B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.53B: what customers paid the company over the last year, before any costs.
What is MRNA’s P/E ratio?
MRNA has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with MRNA?
The business generates net losses as global demand for its COVID-19 vaccine continues to drop sharply. That is one risk on Moderna’s card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Moderna’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. MRNA’s filings on SEC.gov. The Margin Monkey is research, not advice.
